XTL Biopharmaceuticals Ltd ADR (XTLB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, XTL Biopharmaceuticals Ltd ADR (XTLB) has a cash flow conversion efficiency ratio of -0.502x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.01 Million) by net assets ($4.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of XTL Biopharmaceuticals Ltd ADR to measure how many days the company can operate on defensive assets alone.
XTL Biopharmaceuticals Ltd ADR - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how XTL Biopharmaceuticals Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
XTL Biopharmaceuticals Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of XTL Biopharmaceuticals Ltd ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SOLUTIANCE AG NA O.N.
F:SLSA
|
N/A |
|
Desenio Group AB
ST:DSNO
|
0.087x |
|
Libero Copper Corp
V:LBC
|
-0.737x |
|
Rostra AG
F:3330
|
N/A |
|
Puri Global Sukses Tbk Pt
JK:PURI
|
-0.151x |
|
BRADDA HEAD LITHIUM O.N.
F:8CD1
|
0.059x |
|
IL&FS Transportation Networks Limited
NSE:IL&FSTRANS
|
0.000x |
|
Pursuit Minerals Ltd
AU:PUR
|
-0.019x |
Annual Cash Flow Conversion Efficiency for XTL Biopharmaceuticals Ltd ADR (2003–2024)
The table below shows the annual cash flow conversion efficiency of XTL Biopharmaceuticals Ltd ADR from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see XTLB market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.43 Million | $-1.62 Million | -0.298x | +6.52% |
| 2023-12-31 | $2.22 Million | $-707.00K | -0.318x | -41.35% |
| 2022-12-31 | $4.00 Million | $-901.00K | -0.225x | -14.54% |
| 2021-12-31 | $5.33 Million | $-1.05 Million | -0.197x | -44.61% |
| 2020-12-31 | $6.25 Million | $-850.00K | -0.136x | -4.56% |
| 2019-12-31 | $6.98 Million | $-908.00K | -0.130x | -32.67% |
| 2018-12-31 | $8.32 Million | $-816.00K | -0.098x | +68.46% |
| 2017-12-31 | $3.62 Million | $-1.12 Million | -0.311x | +51.77% |
| 2016-12-31 | $2.69 Million | $-1.73 Million | -0.645x | -69.27% |
| 2015-12-31 | $4.89 Million | $-1.86 Million | -0.381x | +27.86% |
| 2014-12-31 | $4.68 Million | $-2.47 Million | -0.528x | -43.33% |
| 2013-12-31 | $6.79 Million | $-2.50 Million | -0.368x | -130.48% |
| 2012-12-31 | $9.42 Million | $-1.51 Million | -0.160x | +69.44% |
| 2011-12-31 | $3.44 Million | $-1.80 Million | -0.523x | -101.63% |
| 2010-12-31 | $2.83 Million | $-735.00K | -0.259x | +99.93% |
| 2009-12-31 | $7.00K | $-2.49 Million | -355.429x | -4691.46% |
| 2008-12-31 | $1.43 Million | $-10.58 Million | -7.418x | -196.07% |
| 2007-12-31 | $8.56 Million | $-21.46 Million | -2.505x | -353.05% |
| 2006-12-31 | $22.76 Million | $-12.59 Million | -0.553x | +40.54% |
| 2005-12-31 | $11.25 Million | $-10.47 Million | -0.930x | -25.79% |
| 2004-12-31 | $19.60 Million | $-14.49 Million | -0.739x | -14.35% |
| 2003-12-31 | $20.61 Million | $-13.33 Million | -0.647x | -- |
About XTL Biopharmaceuticals Ltd ADR
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more